Cargando…

Multicentric Castleman's Disease (CD) in juvenile idiopathic arthritis (JIA) treated with etanercept: coincidence or causal relationship?

Detalles Bibliográficos
Autores principales:	Rossi, L, Martini, G, Sainati, L, Zulian, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334117/ http://dx.doi.org/10.1186/1546-0096-6-S1-P56

Ejemplares similares

An in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
por: Livermore, P, et al.
Publicado: (2008)

PReS-FINAL-2096: Herpes virus infections in patients with juvenile idiopathic arthritis (JIA) treated with etanercept
por: Nicolai, R, et al.
Publicado: (2013)

PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013)

Talus Arthritis Pattern in Juvenile Idiopathic Arthritis (JIA)
por: Alkhreisat, Mohammad, et al.
Publicado: (2019)

Ocular threat in juvenile idiopathic arthritis (JIA)
por: Marvillet, I, et al.
Publicado: (2008)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Time of onset of iridocyclitis (IC) in children with juvenile idiopathic arthritis (JIA)
por: Verazza, S, et al.
Publicado: (2008)

Mandibular condyle destruction in juvenile idiopathic arthritis (JIA)
por: Zak, M, et al.
Publicado: (2008)

Thalidomide: efficacy and side effects in juvenile idiopathic arthritis (JIA)
por: Alpigiani, MG, et al.
Publicado: (2008)

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA)
por: Horneff, G, et al.
Publicado: (2008)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

Juvenile idiopathic arthritis (JIA): can an integrated medicine be possible?
por: Officioso, A, et al.
Publicado: (2011)

Sport and exercise habits in children with juvenile idiopathic arthritis (JIA)
por: Nørgaard, M, et al.
Publicado: (2011)

Pregnancy outcomes in women affected by juvenile idiopathic arthritis (JIA)
por: Alpigiani, Maria Giannina, et al.
Publicado: (2014)

Analysis of ceiling effect and score distribution of outcome measures in juvenile idiopathic arthritis (JIA)
por: Lattanzi, B, et al.
Publicado: (2008)

Sleep, fatigue and quality of life in juvenile idiopathic arthritis (JIA) and Juvenile Dermatomyositis (JDM)
por: Avie, Y Butbul, et al.
Publicado: (2008)

Development and initial validation of the parent acceptable symptom state in juvenile idiopathic arthritis (JIA)
por: Filocamo, G, et al.
Publicado: (2008)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

A meta-analysis to estimate the “real” placebo effect in juvenile idiopathic arthritis (JIA) trials
por: Demirkaya, E, et al.
Publicado: (2011)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Replication of the association of the COG6 gene with juvenile idiopathic arthritis (JIA)
por: Hinks, A, et al.
Publicado: (2011)

Dynamic knee joint function in children with juvenile idiopathic arthritis (JIA)
por: Hansmann, Sandra, et al.
Publicado: (2015)

The successes and challenges of harmonising juvenile idiopathic arthritis (JIA) datasets to create a large-scale JIA data resource
por: Lawson-Tovey, Saskia, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Juvenile diabetes and systemic sclerosis: just a coincidence?
por: Mastrangelo, Greta, et al.
Publicado: (2022)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
por: Öman, Anders, et al.
Publicado: (2021)

Knee disease in juvenile idiopathic arthritis (JIA): correlation between clinical and ultrasonographic findings
por: McCarron, M, et al.
Publicado: (2008)

How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
por: Rouster-Stevens, Kelly, et al.
Publicado: (2008)

Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
por: Mori, Masaaki, et al.
Publicado: (2008)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Psychological characteristics of the patients with juvenile idiopathic arthritis (JIA) of various age groups
por: Stepanenko, NY
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fhhq04cscsvr3ov8u2htb91pmi